XERIS BIOPHARMA HOLDINGS INC
XERSNASDAQTrading Snapshot
- Day Range
- $734.45 – $742.97
- 52-Week Range
- $5.25 – $10.08
- Volume
- $2.06B
- Avg Volume
- $2.75B
- Shares Outstanding
- 172.6M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $292M
- Last Q Revenue
- $92M
- P/E Ratio
- -93.7
- P/S Ratio
- 4.7x
- EPS (TTM)
- $-0.10
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +20.8%
Why Investors Own XERS
- ✓High-growth profile — revenue up +58.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 79% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
XERIS BIOPHARMA HOLDINGS INC
XERS
StockOtter · stockotter.spaceAbout XERIS BIOPHARMA HOLDINGS INC
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
XERIS BIOPHARMA HOLDINGS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift XERS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
XERIS BIOPHARMA HOLDINGS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.